Bill Keller

Despite overhaul of publishing industry, the Gray Lady remains the house organ of America's elite, and Keller sets terms of daily global debate. Hoping to finally monetize large online readership (42 million monthly viewers), plans to put online content behind a paywall in January 2012. Says rumors of print's death have been greatly exaggerated: expects The Times to remain in print for next 10, 20 years. Keller: "Saving The New York Times now ranks with saving Darfur as a high-minded cause." More »

More On Forbes

For as long as talking salaries has been an office taboo, people have wanted to do it. At Vanity Fair in the 1930s, Dorothy Parker, Robert Benchley and Robert Sherwood famously responded to a request from management that employees not disclose their salaries by painting their wages onto signs and wearing them around their necks. read »

The New York Times fired its executive editor, Jill Abramson, this week. This sparked an intense discussion on several topics as rumors flew that The New York Times had paid Ms. Abramson less than her predecessor, Bill Keller, and also that a key reason for the firing was her abrasive management style. Thus, people are wondering if read »

Jill Abramson’s tenure as executive editor of The New York Times was over in the blink of an eye. The questions she raised about gender bias and pay equality in the highest precincts of journalism aren’t going away that quickly.

Over the past couple days, the paper and Abramson — or at least anonymous somebodies in Abramson’s camp — have read »

Back in 1982, when I was 24 and she was 29, Jill Abramson and I worked together at The American Lawyer magazine. Jill lived in Stuyvesant Town with her smart, friendly husband Henry Griggs and their little daughter Cornelia and I lived in the East Village, so Jill and I would sometimes walk home from work together. I found her to be an immensely read »

Jill Abramson, the executive editor of the New York Times, was fired this week and replaced by Dean Baquet, the paper’s managing editor, but the central mystery remains: Why did Arthur Sulzberger Jr., the Times’s publisher, do it?

Was it one too many clashes with the newspaper’s CEO Mark Thompson? Or was Abramson ousted for read »

It is one of the most awkward questions one can ask a colleague, “How much are you making?” In the few times I’ve broached the topic, I’ve usually come away disturbed to discover discrepancies in salary unexplained by experience, education, or seniority. When news broke today that New York Times executive editor Jill Abramson was being replaced, read »

Jill Abramson, whose job as executive editor of The New York Times made her one of the world’s most powerful women, has been fired. Arthur Sulzberger Jr., the publisher of the Times and head of the family that controls it, just notified his staff that managing editor Dean Baquet will succeed Abramson, effective immediately.

Short haul carrier Republic Airways has filed for bankruptcy after labor disputes and pilot shortages cut into the company’s volumes and sales. Although the filing sent Republic Airways shares tumbling nearly 80% on Thursday evening, CEO Bryan Bedford characterized the move as helping take the airline to “new heights.” read »

[Note: This article originally appeared on Timmerman Report, a premium publication for biotech professionals.]

Harvard just got $20 million in cash from Merck & Co. Surely, some industry haters will spit out their coffee over that headline. To those in academia who see their endeavor as that of purely noble truth-seekers and read »

Last week GlaxoSmithKline announced that its CEO, Sir Andrew Witty, would be stepping down from his post in early 2017. As outlined by the Financial Times, his tenure at GSK has been turbulent. Nowhere has that been more evident than in his stance on drug pricing. His concerns that the high drug prices in the U.S. aren’t sustainable read »

A couple weeks ago, I imagined a “dream team“ of people who could break the mold and come up with a more fair, sustainable way for pricing drugs. The goal: Improve access to medicines, improve patient outcomes, and maintain profit incentives for companies to keep developing innovative new ones.

Forbes Video

While nearly all of the FORBES World's Most Powerful have topped the marquee, the higher you go, the exclusiveness and ranks gets thinner. At the peak is the most treasured perk of all, enjoyed only by one person on the list.